Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.
This biotech player is heading for a critical moment.
Wall Street Expects This Growth Stock That's Already Climbed 70% to Almost Double -- And Here's Why.
Overview
In the world of biotech, investors aim to get in on companies working on exciting technologies that could produce game-changing products. It's risky because in the early days of research, many of these technologies are unproven. But if the company is successful and produces safe and effective treatments, revenue and stock performance may skyrocket.
Often, the stock performance comes first. This is because investors, seeing, for example, positive clinical trial data, may jump to get in on the stock well before a product wins approval and begins generating revenue.
Details
Now here's when things get really exciting: The company delivers positive phase 3 results and gets ready to submit the potential product for regulatory approval. And right now, that's exactly what's happening with a biotech growth stock that's climbed more than 70% so far this year. But these gains may be far from over. Wall Street expects the stock to gain another 70% from today's levels over the coming 12 months. Let's check out this exciting story.
Source
Originally published at www.fool.com.
